Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

78 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Next-Generation Sequencing of T and B Cell Receptor Repertoires from COVID-19 Patients Showed Signatures Associated with Severity of Disease.
Schultheiß C, Paschold L, Simnica D, Mohme M, Willscher E, von Wenserski L, Scholz R, Wieters I, Dahlke C, Tolosa E, Sedding DG, Ciesek S, Addo M, Binder M. Schultheiß C, et al. Among authors: dahlke c. Immunity. 2020 Aug 18;53(2):442-455.e4. doi: 10.1016/j.immuni.2020.06.024. Epub 2020 Jun 30. Immunity. 2020. PMID: 32668194 Free PMC article.
Systems Vaccinology Identifies an Early Innate Immune Signature as a Correlate of Antibody Responses to the Ebola Vaccine rVSV-ZEBOV.
Rechtien A, Richert L, Lorenzo H, Martrus G, Hejblum B, Dahlke C, Kasonta R, Zinser M, Stubbe H, Matschl U, Lohse A, Krähling V, Eickmann M, Becker S; VEBCON Consortium; Thiébaut R, Altfeld M, Addo MM. Rechtien A, et al. Among authors: dahlke c. Cell Rep. 2017 Aug 29;20(9):2251-2261. doi: 10.1016/j.celrep.2017.08.023. Cell Rep. 2017. PMID: 28854372 Free PMC article. Clinical Trial.
Polyclonal and convergent antibody response to Ebola virus vaccine rVSV-ZEBOV.
Ehrhardt SA, Zehner M, Krähling V, Cohen-Dvashi H, Kreer C, Elad N, Gruell H, Ercanoglu MS, Schommers P, Gieselmann L, Eggeling R, Dahlke C, Wolf T, Pfeifer N, Addo MM, Diskin R, Becker S, Klein F. Ehrhardt SA, et al. Among authors: dahlke c. Nat Med. 2019 Oct;25(10):1589-1600. doi: 10.1038/s41591-019-0602-4. Epub 2019 Oct 7. Nat Med. 2019. PMID: 31591605 Clinical Trial.
Safety and immunogenicity of a modified vaccinia virus Ankara vector vaccine candidate for Middle East respiratory syndrome: an open-label, phase 1 trial.
Koch T, Dahlke C, Fathi A, Kupke A, Krähling V, Okba NMA, Halwe S, Rohde C, Eickmann M, Volz A, Hesterkamp T, Jambrecina A, Borregaard S, Ly ML, Zinser ME, Bartels E, Poetsch JSH, Neumann R, Fux R, Schmiedel S, Lohse AW, Haagmans BL, Sutter G, Becker S, Addo MM. Koch T, et al. Among authors: dahlke c. Lancet Infect Dis. 2020 Jul;20(7):827-838. doi: 10.1016/S1473-3099(20)30248-6. Epub 2020 Apr 21. Lancet Infect Dis. 2020. PMID: 32325037 Free PMC article. Clinical Trial.
Ebola Virus Disease Survivors Show More Efficient Antibody Immunity than Vaccinees Despite Similar Levels of Circulating Immunoglobulins.
Koch T, Rottstegge M, Ruibal P, Gomez-Medina S, Nelson EV, Escudero-Pérez B, Pillny M, Ly ML, Koundouno FR, Bore JA, Magassouba N, Dahlke C, Günther S, Carroll MW, Addo MM, Muñoz-Fontela C. Koch T, et al. Among authors: dahlke c. Viruses. 2020 Aug 20;12(9):915. doi: 10.3390/v12090915. Viruses. 2020. PMID: 32825479 Free PMC article.
78 results